Anceschi Umberto, Tufano Antonio, Flammia Rocco Simone, Mormando Marilda, Fiori Cristian, Zappalà Orazio, De Concilio Bernardino, Carrara Alessandro, Maria Consiglia Ferriero, Tuderti Gabriele, Brassetti Aldo, Misuraca Leonardo, Bove Alfredo Maria, Mastroianni Riccardo, Appetecchia Marialuisa, Tirone Giuseppe, Porpiglia Francesco, Celia Antonio, Gallucci Michele, Simone Giuseppe
Department of Urology, IRCSS 'Regina Elena' National Cancer Institute, Rome, Italy.
Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy.
Cent European J Urol. 2022;75(4):345-351. doi: 10.5173/ceju.2022.147. Epub 2022 Oct 18.
Several predictive scores to evaluate outcomes of adrenal surgery for unilateral primary aldosteronism (UPA), have been conceived. We compared a novel trifecta that summarizes outcomes of adrenal surgery for UPA with the clinical cure proposed by Vorselaars.
Between March 2011 and January 2022, a multi-institutional dataset was queried for UPA. Baseline, perioperative and functional data were collected. Clinical and biochemical complete and partial success rates according to Primary Aldosteronism Surgical Outcome (PASO) criteria were assessed for the overall cohort. Clinical cure was defined either as normotension without antihypertensive medications or normotension with lower or equal use of antihypertensive medications. Trifecta was defined as the coexistence of ≥50% antihypertensive therapeutic intensity score (TIS) reduction (ΔTIS), no electrolyte impairment at 3-months and no Clavien-Dindo (2-5) complications. Cox regression analyses were used to identify predictors of long-term clinical and biochemical success. For all analyses, a two-sided p <0.05 was considered significant.
Baseline, perioperative and functional outcomes were analyzed. Out of 90 patients, at a median follow-up of 42 months (IQR 27-54) a complete and partial clinical success was observed in 60% and 17.7% of cases while a complete and partial biochemical success was achieved in 83.3% and 12.3% of cases, respectively. Overall trifecta and clinical cure rates were 21.1% and 58.9%, respectively. On multivariable Cox regression analysis, trifecta achievement (HR 2.87; 95% CI 1.45-5.58; p = 0.02) was the only independent predictor of complete clinical success at long-term follow-up.
Despite its complex estimation and more restrictive criteria, trifecta but not clinical cure allows to independently predict composite PASO endpoints on the long run.
已经构思了几种用于评估单侧原发性醛固酮增多症(UPA)肾上腺手术结局的预测评分系统。我们将一种总结UPA肾上腺手术结局的新型三联指标与Vorselaars提出的临床治愈标准进行了比较。
在2011年3月至2022年1月期间,查询了一个多机构数据集以获取UPA患者信息。收集了基线、围手术期和功能数据。根据原发性醛固酮增多症手术结局(PASO)标准评估了整个队列的临床和生化完全缓解率及部分缓解率。临床治愈定义为无需使用抗高血压药物的血压正常,或使用抗高血压药物剂量减少或相同的血压正常。三联指标定义为抗高血压治疗强度评分(TIS)降低≥50%(ΔTIS)、术后3个月无电解质紊乱且无Clavien-Dindo(2-5级)并发症同时存在。采用Cox回归分析确定长期临床和生化缓解的预测因素。所有分析中,双侧p<0.05被认为具有统计学意义。
分析了基线、围手术期和功能结局。90例患者中,中位随访42个月(四分位间距27-54个月),60%的病例观察到临床完全缓解和部分缓解,17.7%的病例观察到临床部分缓解;生化完全缓解和部分缓解分别在83.3%和12.3%的病例中实现。总体三联指标达标率和临床治愈率分别为21.1%和58.9%。多变量Cox回归分析显示,三联指标达标(HR 2.87;95%CI 1.45-5.58;p = 0.02)是长期随访中临床完全缓解的唯一独立预测因素。
尽管三联指标评估复杂且标准更严格,但从长远来看,三联指标而非临床治愈能够独立预测复合PASO终点。